Heberprot-P arrives in the EU
Since being launched on the international market, Heberprot-P has been registered in more than 20 countries and used to treat some 250,000 people worldwide
A delegation of Cuban health professionals arrived to Slovakia May 24, where they will offer assistance in the application of Heberprot-P, a unique medication developed by the island’s Genetic Engineering and Biotechnology Center (CIGB) to treat diabetic foot ulcers, according to a report published on the Cuban Foreign Ministry website.




